All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Miltenyi Biomedicine, Roche, Sobi and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Incyte, and Lilly. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

ASH 2025 | Live congress coverage from the Lymphoma Hub

By Dylan Barrett

Share:

Dec 6, 2025

Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma and CLL.


Stay up to date with the latest developments in lymphoma and CLL, with the Lymphoma Hub’s live social media coverage from the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US.

Loading congress coverage...

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ASH 2025BGB-16673GolcadomideSurovatamigMesutoclaxJNJ-90014496UlviprubartRocbrutinibZamtocabtagene autoleucelRondecabtagene autoleucelSoquelitinibRapcabtagene autoleucelOdronextamabBendamustineTucidinostat AzacitidineBortezomibAzercabtagene zapreleucelMantle cell lymphomaFollicular lymphoma Diffuse large B-cell lymphomaChronic lymphocytic leukemiaSonrotoclaxLarge B-cell lymphomaDexamethasoneBleomycinSmall lymphocytic lymphomaT-cell large granular lymphocytic leukemiaEpcoritamabPirtobrutinibTazemetostatClassical Hodgkin lymphomaVenetoclax PrednisoneLenalidomideMosunetuzumabCyclophosphamideMarginal zone lymphomaGlofitamabAcalabrutinibNivolumabPolatuzumab vedotinPembrolizumabPrimary CNS LymphomaDacarbazineDoxorubicinBrentuximab vedotinMB-105TislelizumabTafasitamabIbrutinibEtoposideObinutuzumabWaldenström macroglobulinemiaRituximabTisagenlecleucel Primary mediastinal large B-cell lymphomaCutaneous T-cell lymphomaZanubrutinib Lisocabtagene maraleucelProcarbazinePeripheral T-cell lymphomaAxicabtagene ciloleucelBrexucabtagene autoleucelBurkitt lymphomaMethotrexateMitoxantroneVincristineBexobrutidegNemtabrutinibAggressive B-cell lymphomasMature T and NK cell neoplasmsFIL_FOLL12ELARABRUINALPINEROSEWOODSWOG 1826STARGLOTRANSCEND FLECHOHD21FLAIREPCORE CLL-1EPCORE NHL-2BELLWAVE-003ATALANTA-1CaDAnCe-101MORNINGSUNEPCORE DLBCL-3BGB-11417-101GAIA/CLL13EPCORE FL-1FIL_RI-CHOPLOC-R01OLYMPIA-3ECWM-1MITHIC-FL2DEBSmart StopZUMA-25DALY 2-EUCRISTALLOBRUIN CLL-314Window-3STAIRTrAVeRseBRUIN CLL-313ROCK-1ALLG-Pacific (NHL35)EPCORE NHL-6Chronic lymphocytic leukemiasIndolent B-cell lymphomasMantle cell lymphomasHodgkin lymphomaConjugated antibodiesAntibody therapyCheckpoint inhibitorsKinase inhibitorsCAR therapyImmune modulatorsChemotherapyNuclear receptor agonistsBCL-2 inhibitorsProteasome inhibitorsHypomethylating agentsT-cell engagersHistone modifiersCELMoDsAmerican Society of Hematology

Your opinion matters

In your experience, when do most CRS/ICANS events occur after lisocabtagene maraleucel infusion?